Autologous stem cell transplantation in the management of multiple myeloma

Morie Gertz, Craig B. Reeder

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Autologous stem cell transplantation has been shown to improve the survival in patients with multiple myeloma. Seven randomized clinical trials have been reported demonstrating the superiority of stem cell transplantation in inducing disease responses, increasing complete remissions, and prolonging event-free survival (Table 10.1). Three trials demonstrated significant prolongation of median survival in newly diagnosed patients [1]. The largest of these trials enrolled 401 patients and, compared with standard therapy, prolonged median survival by almost 1 year [2]. The available therapies in the era of these trials, however, did not include the novel agents, thalidomide, lenalidomide, and bortezomib, and some have questioned the rationale for stem cell transplantation with the advent of novel agents.

Original languageEnglish (US)
Title of host publicationMultiple Myeloma: Diagnosis and Treatment
PublisherSpringer New York
Pages101-124
Number of pages24
ISBN (Print)9781461485209, 9781461485193
DOIs
StatePublished - Jan 1 2014

Fingerprint

Stem Cell Transplantation
Multiple Myeloma
Survival
Thalidomide
Disease-Free Survival
Randomized Controlled Trials
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Gertz, M., & Reeder, C. B. (2014). Autologous stem cell transplantation in the management of multiple myeloma. In Multiple Myeloma: Diagnosis and Treatment (pp. 101-124). Springer New York. https://doi.org/10.1007/978-1-4614-8520-9_10

Autologous stem cell transplantation in the management of multiple myeloma. / Gertz, Morie; Reeder, Craig B.

Multiple Myeloma: Diagnosis and Treatment. Springer New York, 2014. p. 101-124.

Research output: Chapter in Book/Report/Conference proceedingChapter

Gertz, M & Reeder, CB 2014, Autologous stem cell transplantation in the management of multiple myeloma. in Multiple Myeloma: Diagnosis and Treatment. Springer New York, pp. 101-124. https://doi.org/10.1007/978-1-4614-8520-9_10
Gertz M, Reeder CB. Autologous stem cell transplantation in the management of multiple myeloma. In Multiple Myeloma: Diagnosis and Treatment. Springer New York. 2014. p. 101-124 https://doi.org/10.1007/978-1-4614-8520-9_10
Gertz, Morie ; Reeder, Craig B. / Autologous stem cell transplantation in the management of multiple myeloma. Multiple Myeloma: Diagnosis and Treatment. Springer New York, 2014. pp. 101-124
@inbook{e61c6bb4090f48779c0a4ce9f124eff7,
title = "Autologous stem cell transplantation in the management of multiple myeloma",
abstract = "Autologous stem cell transplantation has been shown to improve the survival in patients with multiple myeloma. Seven randomized clinical trials have been reported demonstrating the superiority of stem cell transplantation in inducing disease responses, increasing complete remissions, and prolonging event-free survival (Table 10.1). Three trials demonstrated significant prolongation of median survival in newly diagnosed patients [1]. The largest of these trials enrolled 401 patients and, compared with standard therapy, prolonged median survival by almost 1 year [2]. The available therapies in the era of these trials, however, did not include the novel agents, thalidomide, lenalidomide, and bortezomib, and some have questioned the rationale for stem cell transplantation with the advent of novel agents.",
author = "Morie Gertz and Reeder, {Craig B.}",
year = "2014",
month = "1",
day = "1",
doi = "10.1007/978-1-4614-8520-9_10",
language = "English (US)",
isbn = "9781461485209",
pages = "101--124",
booktitle = "Multiple Myeloma: Diagnosis and Treatment",
publisher = "Springer New York",

}

TY - CHAP

T1 - Autologous stem cell transplantation in the management of multiple myeloma

AU - Gertz, Morie

AU - Reeder, Craig B.

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Autologous stem cell transplantation has been shown to improve the survival in patients with multiple myeloma. Seven randomized clinical trials have been reported demonstrating the superiority of stem cell transplantation in inducing disease responses, increasing complete remissions, and prolonging event-free survival (Table 10.1). Three trials demonstrated significant prolongation of median survival in newly diagnosed patients [1]. The largest of these trials enrolled 401 patients and, compared with standard therapy, prolonged median survival by almost 1 year [2]. The available therapies in the era of these trials, however, did not include the novel agents, thalidomide, lenalidomide, and bortezomib, and some have questioned the rationale for stem cell transplantation with the advent of novel agents.

AB - Autologous stem cell transplantation has been shown to improve the survival in patients with multiple myeloma. Seven randomized clinical trials have been reported demonstrating the superiority of stem cell transplantation in inducing disease responses, increasing complete remissions, and prolonging event-free survival (Table 10.1). Three trials demonstrated significant prolongation of median survival in newly diagnosed patients [1]. The largest of these trials enrolled 401 patients and, compared with standard therapy, prolonged median survival by almost 1 year [2]. The available therapies in the era of these trials, however, did not include the novel agents, thalidomide, lenalidomide, and bortezomib, and some have questioned the rationale for stem cell transplantation with the advent of novel agents.

UR - http://www.scopus.com/inward/record.url?scp=84961306411&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84961306411&partnerID=8YFLogxK

U2 - 10.1007/978-1-4614-8520-9_10

DO - 10.1007/978-1-4614-8520-9_10

M3 - Chapter

AN - SCOPUS:84961306411

SN - 9781461485209

SN - 9781461485193

SP - 101

EP - 124

BT - Multiple Myeloma: Diagnosis and Treatment

PB - Springer New York

ER -